Ascentage Pharma Group International 2025 Sustainability Report
Company: Ascentage Pharma Group International
Sector: Manufacturing
Country: China
Year: 2025
Type: Sustainability Report
Pages: 119
The report highlights Lisaftoclax's July 2025 approval in China and the company's innovation and access-to-healthcare work. It reports 2025 Scope 1 and 2 emissions of 8,137.64 tCO2e and Scope 3 emissions of 1,293.00 tCO2e, alongside a 50% carbon-emissions reduction goal by 2040. It also records 767 employees, 100% training coverage and average training of 8.69 hours per employee.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.